Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Abstract

The journal and the authors apologise for errors in Table 2 of this article that was published in the August issue (vol 167, pp 287–294). The n values were incorrectly published. The correct values are presented below and the table is published in full below.Table 2Observed mean changes from baseline HbA1c, FPG and body weight. Data are observed as mean (s.d.) for all randomised subjects (full analysis set).nBaselineaWeek 16bChange from baselineHbA1c (%) IDegAsp618.5 (1.2)6.7 (1.0)−1.8 (1.1)c AF598.5 (0.9)6.6 (0.6)−1.9 (1.1)c BIAsp 30628.6 (1.0)6.7 (0.7)−1.8 (0.9)cFPG (mmol/l) IDegAsp6111.5 (2.6)6.4 (2.2)−5.1 (2.9) AF5911.8 (2.9)6.5 (1.9)−5.3 (3.0) BIAsp 306211.7 (3.1)7.5 (2.1)−4.3 (3.0)Body Weight (kg) IDegAsp6187.5 (16.3)88.6 (16.9)1.1 (2.8) AF5984.9 (14.3)85.6 (14.9)0.7 (2.5) BIAsp 306291.8 (13.5)93.2 (13.1)1.4 (3.2)aValues at randomisation.bLast observation carried forward.c% points.